Evommune, Inc. (EVMN)

NYSE: EVMN · USD

$6.25

+1.09 (+21.0%)· Recorded snapshot

Market cap	226.6M
Revenue (ttm)	10M
Net income (ttm)	-94.7M
EPS (ttm)	-$4.15
Shares out	36.3M
Volume	6,372,781

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 10M
Net income (ttm): -94.7M
EPS (ttm): -$4.15
Market cap: 226.6M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-52.1

P25 n/aP50 n/aP75 n/a

ROIC-34.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All EVMN indicators

Market & fundamental data

Available fields

178

Groups with data

Currency

USD

Showing 178 of 178 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002044725
Company name	Evommune, Inc.
Country	United States
Country code	US
CUSIP number	30054Y107
Earnings date	2026-11-11
Earnings time	amc
Employees	48
Enterprise value	$34.5M
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2020
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2025-11-06
Is primary listing	Yes
Is SPAC	No
ISIN number	US30054Y1073
Last 10-K release date	2026-03-05
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$226.6M
Market cap category	Micro-Cap
Next earnings date	2026-11-11
Options	Yes
Price	$6.25
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	EVMN
Tags	pharmaceuticals
U.S. state	California
Website	https://www.evommune.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-66.42%
EV/Sales	4.23x
FCF / EV yield	-176.56%
FCF yield	-31.84%
P/B ratio	0.67x
P/S ratio	23.44x
Price / tangible book value	0.84x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Operating margin	-1,018.94%
Pretax margin	-946.68%
Profit per employee	$-2M
Revenue per employee	$208,333
ROA	-31.99%
ROCE	-35.82%
ROE	-52.11%
ROIC	-34.17%
SBC / revenue	128.08%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	4
EPS growth years	1
Gross profit growth	233.33%
Net income growth years	0
Revenue growth	233.33%
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-501,000
Depreciation and amortization	$1.5M
EBIT	$-101.9M
EBITDA	$-100.4M
EPS	$-4.15
FCF per share	$-2.06
Financing cash flow	$274.2M
Free cash flow	$-74.7M
Free cash flow minus SBC	$-87.5M
Gross profit	$10M
Investing cash flow	$-200.9M
Net borrowing	$-451,000
Net cash flow	$-808,000
Net income	$-94.7M
Operating cash flow minus SBC	$-87M
Operating income	$-101.9M
Revenue	$10M
Stock-based compensation	$12.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	16.62
Book value per share	$7.65
Debt / equity	0.03
Long-term assets	$97.7M
Long-term liabilities	$6.9M
Net cash (debt)	$192.2M
Net cash / market cap	81.96%
Net cash growth	123.38%
Net debt / equity	-0.69
Piotroski F-Score	2
Property, plant and equipment	$9.2M
Shareholders' equity	$277.6M
Tangible book value	$277.6M
Tangible book value per share	$7.65
Total assets	$301.9M
Total cash	$200.8M
Total debt	$8.6M
Total liabilities	$24.4M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.05
Current assets	$204.2M
Current liabilities	$17.5M
Current ratio	11.68
Net working capital	$-12.3M
Quick ratio	11.48
Working capital	$186.8M
Working capital turnover	0.07

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1,390.45%
Dividend yield	0%
Shareholder yield	-1,390.45%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$16.11
1D price change	21.03%
1M price change	-26.86%
1M total return	-26.86%
1W price change	15.43%
1W total return	15.43%
20-day SMA	$5.89
200-day SMA	$17.90
3M price change	-45.86%
3M total return	-45.86%
50-day SMA	$9.09
50-day SMA vs 200-day SMA	50under200
52-week high	$33.20
52-week high date	2026-02-10
52-week low	$4.94
52-week low date	2026-10-23
6M price change	-75.16%
6M total return	-75.16%
All-time high	$33.20
All-time high date	2026-02-10
All-time low	$4.94
All-time low date	2026-10-23
Average true range (ATR)	$0.57
Average volume	1.1M
Beta (1Y)	0.81
Change from 52-week high	-81.19%
Change from 52-week low	26.42%
Change from all-time high	-81.3%
Change from all-time low	25.71%
Change from open	13.55%
Day's gap	6.59%
Dollar volume	$39.8M
High price	$7.20
Low price	$5.42
Monthly RSI	0
Open price	$5.50
Position in 52-week range	46.35%
Premarket change	6.59%
Premarket close	$5.16
Premarket price	$5.50
Premarket volume	9.1K
Previous close	$5.16
Price vs 150-day SMA	-61.45%
Price vs 20-day SMA	5.52%
Price vs 200-day SMA	-65.31%
Price vs 50-day SMA	-31.67%
Relative volume	5.86
Return from IPO open	-62.55%
Return from IPO price	-59.63%
RSI	42.49
Sharpe ratio	-0.49
Sortino ratio	-0.73
Volume	6.4M
Weekly RSI	35.95
YTD price change	-63.73%
YTD total return	-63.73%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	19.9M
Float percentage	54.78%
Shares change (QoQ)	7.32%
Shares change (YoY)	1,390.45%
Shares held by insiders	2.5%
Shares held by institutions	61.34%
Shares outstanding	36.3M
Short % of float	14.55%
Short % of shares	7.97%
Short ratio	3.6 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	243

Deeper analysis on EVMN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this EVMN report

Is a complete EVMN research report available?

No complete published report is available for Evommune, Inc. (EVMN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Evommune, Inc. (EVMN)

Price

Financial snapshot

Fair-value bridge

Latest news · EVMN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All EVMN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on EVMN

Frequently asked questions